Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7981 to 7995 of 8900 results

  1. Gouty arthritis: canakinumab (ESNM23)

    This advice has been updated and replaced by NICE guideline NG219.

    Withdrawn advice

  2. Type 1 diabetes: insulin degludec (ESNM24)

    This evidence summary has been updated and replaced by NICE guideline NG17.

    Withdrawn advice

  3. Type 2 diabetes: lixisenatide (ESNM26)

    This evidence summary has been updated and replaced by NICE guideline NG28.

    Withdrawn advice

  4. Alcohol dependence: nalmefene (ESNM29)

    This evidence summary has been replaced by NICE technology appraisal guidance 325.

    Withdrawn advice

  5. Secondary prevention in acute coronary syndrome: rivaroxaban (ESNM27)

    This evidence summary has been replaced by NICE technology appraisal guidance 335

    Withdrawn advice

  6. Asthma: fluticasone/formoterol (Flutiform) combination inhaler (ESNM3)

    This evidence summary has been updated and replaced by NICE guideline NG80.

    Withdrawn advice

  7. Long-acting reversible contraception: subcutaneous depot medroxyprogesterone acetate (DMPA‑SC) (ESNM31)

    This evidence summary has been replaced by the long-acting reversible contraception: implementation resource summary.

    Withdrawn advice

  8. Chronic obstructive pulmonary disease: indacaterol/glycopyrronium (Ultibro Breezhaler) (ESNM33)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Withdrawn advice

  9. Preventing recurrence of Clostridium difficile infection: bezlotoxumab (ES13)

    This advice has been updated and replaced by NICE guideline NG199.

    Withdrawn advice

  10. Non-cystic fibrosis bronchiectasis: inhaled tobramycin (ES12)

    This evidence summary has been updated and replaced by NICE guideline NG117.

    Withdrawn advice

  11. Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates (ES15)

    This evidence summary has been updated and replaced by NICE guideline NG101.

    Withdrawn advice

  12. Obese, overweight with risk factors: liraglutide (Saxenda) (ES14)

    This evidence summary has been updated and replaced by NICE technology appraisal guidance 664.

    Withdrawn advice

  13. Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy) (ES18)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Withdrawn advice

  14. Doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy (ES20)

    This evidence summary has been updated and replaced by NICE guideline NG201.

    Withdrawn advice

  15. Antimicrobial prescribing: Ceftazidime/avibactam (ES16)

    This evidence summary has been updated and replaced by NICE antimicrobial health technology evaluation guidance on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.  

    Withdrawn advice